Maynard Um
-
-
-
-
-
-
-
Rocket Pharmaceuticals (RCKT) PT Raised to $11 at Leerink Partners
-
-
-
-
-
-
-
FDA accepts Rocket Pharmaceuticals' resubmitted gene therapy application
-
-
-
-
-
-
-
Rocket Pharmaceuticals CFO Aaron Ondrey to resign September 5
-
-
-
-
-
-
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $10 at Canaccord Genuity
-
-
-
-
-
-
-
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action - Hagens Berman
-
-
-
-
-
-
-
INVESTOR REMINDER: Berger Montague Notifies Rocket Pharmaceuticals (RCKT) Investors of a Class Action Lawsuit and Deadline
-
-
-
-
-
-
-
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
-
431,647 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

